Free Trial
NYSE:RFL

Rafael Q1 2025 Earnings Report

Rafael logo
$1.52 -0.04 (-2.56%)
As of 10:15 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rafael EPS Results

Actual EPS
-$0.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, December 11, 2024
Conference Call Time
7:00AM ET

Rafael Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Rafael Devers Player Props: July 25, Giants vs. Mets
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile

More Earnings Resources from MarketBeat